Do cancer treatments increase a patient's risk of cardiovascular disease?

A CT scan used for a radiation therapy treatment plan for breast cancer shiows the close proximity of the heart, which can suffer collateral damage from radiation and chemotherapy treatments for cancer.

A CT scan used for a radiation therapy treatment plan for breast cancer shows the close proximity of the heart, which can suffer collateral damage from radiation and chemotherapy treatments for cancer. 

Older cancer survivors appear to face higher risks of stroke, heart attack and heart failure. Early screening and preventative measures can help.

FDA clears new software for AI-powered CCTA assessments

Left, coronary CT angiography of a vessel showing plaque heavy calcium burden. Right, image showing color code of various types of plaque morphology showing the complexity of these lesions. The right image was processed using the FDA cleared, AI-enabled plaque assessment from Elucid.

Elucid's AI analysis software in action. The left image shows coronary CT angiography of a vessel showing plaque heavy calcium burden. The right image, processed by Elucid's software, highlights the various types of plaque morphology of these lesions.

Elucid's PlaqueIQ was trained to turn CCTA images into interactive 3D reports that help physicians visualize the presence of atherosclerosis.

New-look TAVR valve recently acquired by Edwards may reduce risk of coronary obstruction

Performing transcatheter aortic valve replacement (TAVR) with the J-Valve transcatheter heart valve (THV) may help limit the risk of coronary artery obstruction (CAO) in high-risk patients, according to a new study published in Clinical Interventions in Aging.[1]

The J-Frame TAVR valve. (A)The prosthesis consists of a frame and 3 “U-shaped” claspers. (B) The crown-like frame. (C) Connection between the frame and the claspers. Images and captions courtesy of Clinical Interventions in Aging.

Early data suggest the J-Valve transcatheter heart valve could help care teams avoid a rare, but often fatal TAVR complication when treating high-risk patients. 

FDA clears new device for valve-in-valve TAVR patients at risk of coronary obstruction

Pi-Cardia ShortCut TAVR device. According to Pi-Cardia, ShortCut is the first medical device of its kind; interventional cardiologists use it to split valve leaflets in patients who have been recommended for valve-in-valve TAVR and face a heightened coronary obstruction risk.

Interventional cardiologists use the ShortCut device to split valve leaflets in patients who have been recommended for valve-in-valve TAVR and face a heightened coronary obstruction risk. Image courtesy of Pi-Cardia. 

ShortCut, which gained the FDA’s breakthrough device designation back in January, is used to split valve leaflets and reduce the risk of obstruction.